30 research outputs found

    Diabetes in women: The global perspective

    No full text

    WHO Global report on diabetes: A summary

    No full text

    The Middle East

    No full text

    Nutrition, diabetes and tuberculosis in the epidemiological transition

    No full text
    The original publication is available at http:/www.plosone.orgBackground: Diabetes prevalence and body mass index reflect the nutritional profile of populations but have opposing effects on tuberculosis risk. Interactions between diabetes and BMI could help or hinder TB control in growing, aging, urbanizing populations. Methods and Findings: We compiled data describing temporal changes in BMI, diabetes prevalence and population age structure in rural and urban areas for men and women in countries with high (India) and low (Rep. Korea) TB burdens. Using published data on the risks of TB associated with these factors, we calculated expected changes in TB incidence between 1998 and 2008. In India, TB incidence cases would have increased (28% from 1.7 m to 2.1 m) faster than population size (22%) because of adverse effects of aging, urbanization, changing BMI and rising diabetes prevalence, generating an increase in TB incidence per capita of 5.5% in 10 years. In India, general nutritional improvements were offset by a fall in BMI among the majority of men who live in rural areas. The growing prevalence of diabetes in India increased the annual number of TB cases in people with diabetes by 46% between 1998 and 2008. In Korea, by contrast, the number of TB cases increased more slowly (6.1% from 40,200 to 42,800) than population size (14%) because of positive effects of urbanization, increasing BMI and falling diabetes prevalence. Consequently, TB incidence per capita fell by 7.8% in 10 years. Rapid population aging was the most significant adverse effect in Korea. Conclusions: Nutritional and demographic changes had stronger adverse effects on TB in high-incidence India than in lower-incidence Korea. The unfavourable effects in both countries can be overcome by early drug treatment but, if left unchecked, could lead to an accelerating rise in TB incidence. The prevention and management of risk factors for TB would reinforce TB control by chemotherapy. © 2011 Dye et al

    The Open House / The Open Archive: Unfolding the domestic archive of Gojka Vukovića 11

    No full text
    The body is an unfolding archive, containing material layers, fossilized remnants of past memories, skin lesions of still visible trauma. The body is a daily carrying agent of intersections, between the outside-inside and inside-inside, in which there is a radicality in considering the ongoing daily or domestic for the institutional. The archive could be an unfolding institution, where fluid embodiments are archived, bodies collide onto Others, objects transfer knowledge, and events are mapped. The body and the archive are both subject to time; time as carrier of events, time as agent in the impermanence or transience of material, narrative, and memory. Time as challenger of the techniques and stability of knowledge. Transitioning the fossilized narratives in trauma is to disrupt the notion of archiving, through movement in its collection, transferring the knowledge from the fixed object.Neretva Recollection: Materiality of War, Flowing Memories and Living ArchiveArchitecture, Urbanism and Building Science

    Global Guideline for Type 2 Diabetes

    No full text
    There is now extensive evidence on the optimal management of diabetes, offering the opportunity of improving the immediate and long-term quality of life of those with diabetes. Unfortunately such optimal management is not reaching many, perhaps the majority, of the people who could benefi t. Reasons include the size and complexity of the evidencebase, and the complexity of diabetes care itself. One result is a lack of proven cost-effective resources for diabetes care. Another result is diversity of standards of clinical practice. Guidelines are one part of a process which seeks to address those problems. Many guidelines have appeared internationally, nationally, and more locally in recent years, but most of these have not used the rigorous new guideline methodologies for identifi cation and analysis of the evidence. Many countries around the world do not have the resources, either in expertise or fi nancially, that are needed to develop diabetes guidelines. Also such a repetitive approach would be enormously ineffi cient and costly. Published national guidelines come from relatively resource-rich countries, and may be of limited practical use in less well resourced countries. In 2005 the fi rst IDF Global Guideline for type 2 diabetes was developed. This presented a unique challenge as we tried to develop a guideline that is sensitive to resource and costeffectiveness issues. Many national guidelines address one group of people with diabetes in the context of one healthcare system, with one level of national and health-care resources. This is not true in the global context where, although every health-care system seems to be short of resources, the funding and expertise available for health-care vary widely between countries and even between localities. Despite the challenges, we feel that we found an approach which is at least partially successful in addressing this issue which we termed ‘Levels of care’ (see next page). This guideline represents an update of the fi rst guideline and extends the evidence base by including new studies and treatments which have emerged since the original guideline was produced in 2005. Funding is essential to an activity of this kind. IDF is grateful to a diversity of commercial partners for provision of unrestricted educational grants.Fil: Aschner, Pablo. International Diabetes Federation Guideline Development Group; BélgicaFil: Beck Nielsen, Henning. International Diabetes Federation Guideline Development Group; BélgicaFil: Bennet, Peter. International Diabetes Federation Guideline Development Group; BélgicaFil: Boulton, Andrew. International Diabetes Federation Guideline Development Group; BélgicaFil: Colagiuri, Ruth. International Diabetes Federation Guideline Development Group; BélgicaFil: Colagiuri, Stephen. International Diabetes Federation Guideline Development Group; BélgicaFil: Franz, Marion. International Diabetes Federation Guideline Development Group; BélgicaFil: Gadsby, Roger. International Diabetes Federation Guideline Development Group; BélgicaFil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Cientifico Tecnológico La Plata. Centro de Endocrinologia Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata; Argentina. International Diabetes Federation Guideline Development Group; BélgicaFil: Home, Philip. International Diabetes Federation Guideline Development Group; BélgicaFil: McGill, Marg. International Diabetes Federation Guideline Development Group; BélgicaFil: Manley, Susan. International Diabetes Federation Guideline Development Group; BélgicaFil: Marshall, Sally. International Diabetes Federation Guideline Development Group; BélgicaFil: Mbanya, Jean Claude. International Diabetes Federation Guideline Development Group; BélgicaFil: Neil, Andrew. International Diabetes Federation Guideline Development Group; BélgicaFil: Ramachandran, Ambady. International Diabetes Federation Guideline Development Group; BélgicaFil: Ramaiya, Kaushik. International Diabetes Federation Guideline Development Group; BélgicaFil: Roglic, Gojka. International Diabetes Federation Guideline Development Group; BélgicaFil: Schaper, Nicolaas. International Diabetes Federation Guideline Development Group; BélgicaFil: Siminerio, Linda. International Diabetes Federation Guideline Development Group; BélgicaFil: Sinclair, Alan. International Diabetes Federation Guideline Development Group; BélgicaFil: Snoek, Frank. International Diabetes Federation Guideline Development Group; BélgicaFil: Van Crombrugge, Paul. International Diabetes Federation Guideline Development Group; BélgicaFil: Vespasiani, Giacomo. International Diabetes Federation Guideline Development Group; BélgicaFil: Viswanathan, Vijay . International Diabetes Federation Guideline Development Group; Bélgic
    corecore